The Winship Cancer Institute (Winship) has solicited extensive Input from both external and internal advisory groups and leadership committees for the planning and evaluation of its current progress, continued advancement, and the establishment of future goals and objectives. In the last reporting period, Strategically composed internal and external committees have enabled Winship to elevate the science it performs. The internal and external mechanisms discussed in this section provide essential guidance on all aspects of Winship, and include the following groups: External Planning and Evaluation: External Advisory Board (EAB), External Administrative Advisory Board, and External Clinical Trials Advisory Boards;and Internal Planning and Evaluation: Winship Internal Advisory Board, Winship Executive Committee, Scientific Research Council, Shared Resource Directors Meeting, Shared Resource Oversight Committee, Membership Committee, Shared Resource Allocation Committee, Space Resource Allocation Committee, Administrative Council, and Winship Clinical Council. Guidance and direction gathered from these many committees has been critical to the advancement of the Winship Cancer Institute. The input from these groups played a major role in the development of the 2010-2015 Winship Strategic Plan. That document has provided Winship a roadmap during the funding cycle proposed in this application. The funds requested in addition to committed institutional funds will provide support for these important advisory endeavors.

Public Health Relevance

The Planning and Evaluation process has been instrumental in Winship's many successes. Each advisory structure works to ensure that Winship's priorities are understood and strategically managed to allow the cancer center to continue to develop and achieve a comprehensive set of goals.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
United States
Zip Code
Mukherjee, Subhas; Tucker-Burden, Carol; Kaissi, Emily et al. (2018) CDK5 Inhibition Resolves PKA/cAMP-Independent Activation of CREB1 Signaling in Glioma Stem Cells. Cell Rep 23:1651-1664
Thompson, Jeffrey A; Christensen, Brock C; Marsit, Carmen J (2018) Methylation-to-Expression Feature Models of Breast Cancer Accurately Predict Overall Survival, Distant-Recurrence Free Survival, and Pathologic Complete Response in Multiple Cohorts. Sci Rep 8:5190
Sadigh, Gelareh; Holder, Chad A; Switchenko, Jeffrey M et al. (2018) Is there added value in obtaining cervical spine MRI in the assessment of nontraumatic angiographically negative subarachnoid hemorrhage? A retrospective study and meta-analysis of the literature. J Neurosurg 129:670-676
Allen, Samuel C; Lohani, Minisha; Hendershot, Kristopher A et al. (2018) Patient perspectives on compensation for biospecimen donation. AJOB Empir Bioeth 9:77-81
Cassidy, Richard J; Switchenko, Jeffrey M; Yushak, Melinda L et al. (2018) The importance of surgery in scalp angiosarcomas. Surg Oncol 27:A3-A8
Owonikoko, Taofeek K; Busari, Adeniyi K; Kim, Sungjin et al. (2018) Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. Oncology 95:138-146
Koff, Jean L; Li, Jing-Xia; Zhang, Xinyan et al. (2018) Impact of the posttransplant lymphoproliferative disorder subtype on survival. Cancer 124:2327-2336
Dhere, Vishal; Edelman, Scott; Waller, Edmund K et al. (2018) Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. Leuk Lymphoma 59:837-843
Dennison, Cori; King, Adrian R; Rutledge, Hannah et al. (2018) HPV Vaccine-Related Research, Promotion and Coordination in the State of Georgia: A Systematic Review. J Community Health :
Pillai, Rathi N; Behera, Madhusmita; Owonikoko, Taofeek K et al. (2018) Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer 124:271-277

Showing the most recent 10 out of 331 publications